About the job
ABOUT US
At Invivyd, Inc., we are committed to addressing the needs of over 9 million immunocompromised individuals in the United States. Our mission is to provide protection from serious viral infectious diseases, starting with SARS-CoV-2. Leveraging a unique, integrated technology platform, we aim to develop world-class antibodies that can adapt to emerging viral threats.
Recent Milestones:
In March 2024, we proudly received emergency use authorization (EUA) from the U. S. FDA for one of our monoclonal antibody candidates. Furthermore, in October 2025, we cleared our Investigational New Drug (IND) application, advancing our clinical program for VYD2311, a groundbreaking monoclonal antibody designed to prevent COVID-19.
Join us in making a significant difference. Become part of Invivyd.
